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Abstract
Background: Attention and inhibition are core executive-function deficits in FRagile X syndrome (FXS). This pilot
study evaluated the feasibility, reproducibility, and clinical relevance of the KiTAP, a computer-based pictorial
measure of attention and inhibition with an enchanted-castle theme, in an FXS cohort.
Methods: The 8-subtest KiTAP battery (as many subtests as each could perform) was given to 36 subjects with
FXS, of variable age and cognitive/behavioral functioning, and 29 were retested, with an interval of 2 to 4 weeks
between sessions. Subjects were rated by parents on the Aberrant Behavior Checklist-Community Edition (ABC-C)
and Behavior Assessment System for Children, Second Edition (BASC-2). Feasibility, ceiling and basal effects, and
data range and distribution analyses were used to eliminate outliers and invalid data points. Reproducibility of
scores was analyzed using intraclass correlation coefficients (ICCs) and validity/clinical relevance was assessed by
correlating KiTAP scores with ABC-C and BASC-2 scores.
Results: Most of the participants with FXS were able to complete the Alertness, Distractibility, Flexibility, and Go/
NoGo subtests.About 50 to 60% completed the Visual Scanning and Vigilance subtests, and 20 to 25% completed
the Sustained Attention and Divided Attention subtests. A panel of seven scores from four subtests were identified
as feasible for most subjects, lacked excessive ceiling, basal, or learning effects, exhibited an acceptable range and
distribution of scores, had good reproducibility (ICC > 0.7), and correlated with behavioral ratings for hyperactivity
or attention (P < 0.01). Only minor differences in performance on the KiTAP were seen between mental age-
matched cohorts of subjects with FXS and non-FXS intellectual disability.
Conclusions: The KiTAP can be administered to cohorts with FXS over a wide range of function with valid
reproducible scores. With additional validation, it could represent a useful outcome measure for assessment of
attention/executive-function abilities in clinical trials targeted to these core deficits in FXS.
Background
Fragile X syndrome (FXS) is the most common known
inherited cause of intellectual disability (ID), learning dis-
ability, and autism, with an estimated frequency in the
range of about 1:2500 to 1:4000 [1]. FXS results from a
trinucleotide repeat (CGG) expansion mutation of more
than 200 repeats (full mutation) in the promoter of
FMR1 (Fragile X mental retardation 1 gene), which leads
to transcriptional silencing of FMR1, and loss or signifi-
cant reduction of expression of the gene product, the
Fragile X mental retardation protein (FMRP). FMRP is
an RNA-binding protein that acts as a negative modula-
tor of dendritic translation. Loss of FMRP results in
excessive and dysregulated dendritic translation, produ-
cing aberrant dendritic morphology and synaptic plasti-
city, and leading to abnormal development and cognition
[2-4]. In addition to intellectual disability, the resultant
behavioral phenotype is characterized by prominent defi-
cits in attention and inhibitory control; autistic symptoms
including social and communication deficits, and
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stereotypic behavior; social anxiety and withdrawal;
hyperarousal; sensory defensiveness; and gaze aversion
[5,6].
Recent advances in the neurobiology of FXS have sug-
gested that many of the phenotypic features of the disor-
der arise from enhanced activity of translational
activation pathways regulated by metabotropic glutamate
receptors 1 and 5 (mGluR1, mGluR5), as a result of
absence of FMRP [7]. In support of this, most known
phenotypes in the mouse and fly models of FXS (which
lack FMRP) can be reversed by pharmacologically [8] or
genetically [9] downregulating these pathways. These
groundbreaking studies have set the stage for pharmaco-
logical trials in humans with FXS, designed to target the
excess activity in mGluR-regulated translational pathways
in neurons [10].
Thus, there is an urgent need to develop objective and
well-validated outcome measures that assay core FXS phe-
notypes. Boys with FXS show larger attention and execu-
tive function (EF) deficits than do mental age (MA)-
matched boys with Down syndrome or typically develop-
ing boys, particularly in areas involving switching attention
and inhibiting repetitious behavior [11]. Thus, EF and
inhibition problems such as hyperactivity, impulsiveness,
and distractibility are thought to be core features of FXS,
occurring in about 80 to 90% of males and at least half of
females in survey studies [12,13]. Behavior-rating scales,
regarded as the standard means of assessing these symp-
toms, are subject to problems of rater bias and placebo
effects. Continuous performance tasks (CPT) can more
objectively measure EFs, and have the benefit of being
responsive to relatively short-term medication treatments,
making them a potentially useful type of efficacy test for
early phase clinical trials and for testing response to inter-
ventions in clinic [14-16]. Efforts to use CPTs to measure
function in these areas have been problematic in FXS
because of the cognitive impairment and widely varying
levels of function. Previous CPTs used in medication trials
in FXS have been too difficult for the majority of partici-
pants (for example, the Integrated Visual and Auditory
(IVA) CPT [17]) or too easy for the higher-functioning
and adult participants, resulting in a high frequency of
ceiling scores (for example, the North Carolina Fragile X
Project CPT (FXCPT)[18] Clinical experience of patients
with FXS suggests that standard CPTs used in clinical
practice, such as the Connors CPT, tend to be too difficult
or too long for many individuals with FXS, thus meaning-
ful data cannot be obtained, or the individual loses interest
and does not complete the task. Most CPTs used in clini-
cal practice such as the IVA+Plus (BrainTrain, Richmond,
VA, USA) are validated with a lower age limit of 5 to 6
years. Because the average MA of adult males with FXS is
5 to 6 years [19], these tasks lack the range to accurately
measure the abilities of at least half of adult males with
FXS and of less than half of younger males who have a
lower average MA. Many of these CPTs are not interesting
to the participants, presenting just simple numerals for
subject responses, and are administered over a longer time
period than most males with FXS can tolerate. Although
the tests are designed to be uninteresting in order to test
attention focusing over time in the general population, a
large fraction of the FXS population, in whom ability to
maintain attention and EF is much more impaired, will
often discontinue the task after a short period of coopera-
tion. Refusal to perform tasks perceived as difficult or long
is a major problem in testing of individuals with FXS [20],
and it is documented that boys with FXS have difficulty
completing executive-function tasks [21]. By contrast,
using a simplified test with limited range such as the
North Carolina FX-CPT, may result in higher-functioning
individuals with FXS showing only ceiling scores [21].
The Test of Attentional Performance for Children
(Testbatterie zur Aufmerksamkeitsprüfung für Kinder;
KiTAP) is a computer-based CPT and EF battery [22]
that has not previously been used to measure cognitive
function in subjects with FXS. The KiTAP was adapted
for use in children from the Tests of Attentional Perfor-
mance (TAP), a test used since the late 1990s to measure
attention and EF performance in adults with various
medical, neurological, and psychiatric conditions. KiTAP
and TAP have been translated from the original German
into validated versions in English, French, Spanish, and
Italian [23]. The KiTAP was devised to be interesting to
children, with an enchanted-castle theme as opposed to
abstract stimuli, and has been used to show attentional
impairment, with slower reaction times and increases in
errors and omissions correlating with decrements in
intelligence quotient (IQ) in liver-transplanted 6 to 12-
year-old children [24], increased impulsivity (false
alarms) in lead-exposed 8 to 12-year-old children that
are more evident than IQ decrements [25], and improve-
ment in Sustained Attention measures after administra-
tion of methylphenidate to 5 to 12-year-old children with
attention deficit hyperactivity disorder [16]. The KiTAP
is composed of eight tests that vary in length and diffi-
culty level, thus it may be possible to use this test to mea-
sure attentional function over the broad range of
intellectual ability present in a cohort with a disorder
such as FXS. Other reasons for choosing the KiTAP to
study FXS are the visual nature of the test, given the high
preference for visual stimuli seen for subjects with FXS,
and the identifiable and high-interest ‘characters’ pre-
sented in the enchanted-castle theme.
In this study, we sought to determine the feasibility
(level of function required to achieve scores on different
subtests without ceiling or basal effects), reproducibility
(consistency of scores in a test/retest setting), and validity
(correlation with meaningful measures of maladaptive
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behavior) of the subtests of the KiTAP in a population
with FXS. Additionally, scores were compared with those
of MA controls with ID as a means of evaluating specifi-
city of performance patterns on the KiTAP in FXS.
Methods
The study was approved by the institutional review
board at Rush University Medical Center (RUMC), and
all participants or their parents signed informed consent
according to an approved protocol.
Participants
Participants with FXS were recruited through the Fragile
X Clinic and Research Program at RUMC, In total, 36
participants (28 male, 8 female; mean ± standard devia-
tion (SD) 18.0 ± 10.24 years of age, range 7 to 50) with
the full Fragile X mutation confirmed by standard test-
ing using Southern blot combined with PCR. All partici-
pants were tested using the computer-based KiTAP test.
Subject participation was not limited by age, gender or
IQ score because the intent of the study was to evaluate
a wide range of subjects to determine the age and func-
tional range over which the KiTAP could be used as an
outcome measure in clinical trials with subjects with
FXS. It was important to evaluate the KiTAP in both
genders, and in both children and adults, given that
trials of new targeted treatments for FXS would prob-
ably involve all these groups. However, all subjects
tested were verbal and able to speak at least in phrases,
and all had sufficient receptive language to follow basic
directions.
When available, cognitive (IQ) assessments were
obtained from previous tests (within the past 2 years for
subjects under 15 years of age, and within the past 5
years for subjects over 15 years of age at the time of the
IQ test) performed at RUMC or from psychological
assessments at the participant’s school. Subjects for
whom IQ test results were not available were not pre-
cluded from participating in the study. IQ assessments
represented scores from the Wechsler Intelligence Scale
for Children (WISC), Wechsler Adult Intelligence Scale,
or Stanford-Binet tests, and were available for 24 (17
males and 7 female) participants with FXS. MA was cal-
culated from IQ using the formula
MA = IQ/100× chronological age,
with a maximum value of 15 used for chronological
age.
The comparison cohort, consisting of 25 individuals
with ID (13 male and 12 female; mean ± SD 11.4 ± 4.4
years of age. range 5 to 24), was recruited and tested
using identical protocols at the Medical Investigation of
Neurodevelopmental Disorders (MIND) Institute at UC
Davis. This group consisted of 12 subjects with idio-
pathic ID, 8 with Down syndrome, 2 with fetal alcohol
syndrome, 1 with 17q21.31 deletion syndrome, 1 with
22q11.2 deletion syndrome, and 1 with ID and autism.
IQ measures, performed with the WISC or Stanford-
Binet tests, were available for all ID participants.
Although the FXS and ID subjects were tested at differ-
ent sites, the methods for administration of the KiTAP
were standardized as much as possible through phone
conferences and a face-to-face meeting. The ID group
was examined to see if there were differences in perfor-
mance patterns that might be attributed to the FXS phe-
notype alone rather than to general ID. For this purpose,
retest was not necessary, and so the ID group was not
retested.
Distribution of psychotropic medication use in the
FXS group was as follows: no drug (14 subjects); one
drug (10 subjects), two drugs (8 subjects), and three
drugs (2 subjects). Medications used were stimulants (15
subjects), selective serotonin uptake inhibitors (SSRIs)/
antidepressants (10 subjects), antipsychotics (4 subjects),
and lithium (1 subject).. Distribution of psychotropic
medication use in the ID group was: no drug (18 sub-
jects), one drug (3 subjects), two drugs (3 subjects), and
three drugs (1 subject). Medications used were stimu-
lants (2 subjects), SSRIs/antidepressants (2 subjects),
antipsychotics (4 subjects), valproic acid (1 subject), and
clonidine (2 subjects).
KiTAP
The KiTAP is composed of eight subtests designed
around a theme (an enchanted castle) specifically
designed to be accessible to young children, thus provid-
ing more motivation to sustain interest in testing than
CPTs and other EF batteries based on abstract symbols.
Each subtest measures a different aspect of cognition:
alertness, distractibility, divided attention, flexibility, reac-
tion control (inhibition), sustained attention, vigilance,
and visual scanning. The Alertness subtest (The Witch)
requires subjects to tap a button every time a stimulus (a
witch) appears on the screen. The Distractibility subtest
(The Happy and Sad Ghosts) requires subjects to tap a
button when a target stimulus (a sad ghost) appears on
the screen while ignoring distracters that appear shortly
before the stimulus; subjects are supposed to ‘cheer up’
the sad ghost by pushing the button and must not
respond when the happy ghost because it does not need
cheering up. The Flexibility subtest (The Dragons’
House) requires subjects to alternate between identifying
blue and green dragons which seem on random sides of
the screen by tapping one of two buttons. The Go/NoGo
or inhibition subtest (The Bat and the Cat) requires sub-
jects to tap a button when the target stimulus (a bat) is
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presented, while refraining from hitting the button for
the non-target stimulus (a cat). The Visual Scanning
subtest (The Witches’ Parade) requires subjects to scan a
grid of 25 witches; subjects press one button if all witches
are flying in the same direction, and hit a second button
if one of the witches is flying in the opposite direction.
The Vigilance subtest (The Mirror) is similar to Go-
NoGo, but the target stimulus (a ghost with orange eyes)
appears infrequently, and the test is much longer
(approximately 10 minutes). The Sustained Attention
subtest (The Ghost’s Ball) features a sequence of differ-
ent-colored ghosts; subjects press a button when two
ghosts of the same color appear sequentially. The Divided
Attention subtest (The Owl) is the only task requiring
processing of an auditory stimulus in addition to visual
stimuli, and requires subjects to simultaneously listen to
a series of high and low owl sounds and watch for target
stimuli (owls with closed eyes). Subjects must press a
button either when a sound is repeated or when the tar-
get stimulus appears.
Subjects spent up to 90 minutes completing all KiTAP
subtests if they were able to perform the entire test (only
five subjects). Most subjects spent about 30 minutes
doing the test, in which they completed 4 to 5 subtests,
but were unable to focus upon, or did not understand
what to do in subsequent longer subtests. Subtests were
administered in the order: Alertness, Distractibility, Flex-
ibility, Go/NoGo, Visual Scanning, Vigilance, Sustained
Attention, and Divided Attention. Because the last four
are much longer tasks, and based on previous experience
of the length of task that typically functioning individuals
with FXS can tolerate, a decision was made to begin with
the subtests most likely to be completed by a wide range
of participants, and to leave the most difficult and longest
subtests (Sustained Attention and Divided Attention)
until last. We continued to administer subtests of
increasing length and difficulty until the subject refused
to do any more, until it became clear to the examiner
that the participant was not making any real attempt to
perform the task, or until the subject was not able to
show that they understood the sample pretest. Although
there is the possibility that this testing order may have
introduced bias into the analysis of the ability of subjects
with FXS to complete the subtests, the testing order was
necessary, based on initial experience with pilot subjects,
as administering the longer and more difficult tests first
was likely to lead to refusal, thus precluding later admin-
istration of the tests the subjects would be most likely
able to complete. The order of test administration was
therefore driven predominantly by the length of the task
and the restrictions posed by the limited attention of sub-
jects with FXS. Further, it is important in clinical trials or
for interventions in the clinic to use the same test order
before and after administration of the intervention, and
the most important focus of this study was to determine
the reliability of the KiTAP subtests for intervention and
longitudinal studies that would involve multiple testing
sessions.
During the tests, subjects were aided by a research
assistant (RA). Before the start of each subtest, the RA
explained the goal of the test. The subject then took a
short pretest to allow their understanding to be evalu-
ated, and if necessary repeated the pretest after further
explanation, up to a maximum of three pretests. If the
subject was ultimately able to perform the pretest for a
given subtest correctly, and the RA perceived that the
subject understood the test, the subtest was then admi-
nistered. If the subject could not show that they under-
stood what to do on the subtest, the subtest was listed
as ‘not feasible’ for that subject. The RA also encouraged
subjects to continue working, and gave positive reinfor-
cement about performance during subtests, provided
breaks between subtests when necessary, and dismissed
subjects when they finished all subtests or were judged
unwilling or unable to continue testing. The administra-
tion method was consistent between both centers (Rush
and UC Davis), including the scripts used to explain
tests to subjects and the prompting strategies. The
scripts used to explain the task for the pretest were
those in the KiTAP instruction manual, but these were
repeated and rephrased in simpler language (same con-
tent) when subjects did not understand and were unable
to perform the pretest correctly. Prompts to encourage
the subjects to continue working on the task were given
when they stopped paying any attention to the screen
and started to do something else or were clearly no
longer engaged in the testing (for example, ‘Watch the
computer, we have to find the witches.’). Subjects were
given non-specific positive feedback for continuing to
work regardless of whether they were giving accurate
responses or not (for example, ‘You’re doing a really
good job with this test today.’). Subjects were not helped
with the test or told to push the button when stimuli
appeared. As would be expected, the number of
prompts required varied depending on the subject.
KiTAP retest
Of the 36 subjects with FXS who were tested with the
KiTAP, 29 were retested 2 to 3 weeks later by the same
tester in the same setting. The other seven subjects (five
male, two females; mean ± SD 18.3 ± 12.4 years of age,
range 9 to 44) were not retested because of scheduling
issues. No changes in psychotropic medication were
allowed between testing sessions. IQ data were available
for 22 (16 male and 6 female) subjects who completed
retesting.
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Behavioral validation measures
At the initial session, parents of all participants, includ-
ing adults who consented for themselves, filled out both
the Behavior Assessment System for Children-Second
Edition (BASC-2) [26] and Aberrant Behavior Checklist-
Community Edition (ABC-C) [27] to allow correlation
of performance on the KiTAP with ratings of each sub-
ject’s hyperactivity and attentional function in daily life.
The ABC-C is the most widely used scale to quantify
behavioral symptoms in individuals with ID including
FXS [17,28], and is considered the most valid currently
available scale to assess hyperactivity and impulsive
behavior for a cohort of subjects with FXS. The ABC-C
is a 58-item parent- or caregiver-rated scale designed to
assess adaptive and maladaptive behavior of intellec-
tually disabled people. It is divided into five subscales:
Irritability (15 items), Lethargy/Social Withdrawal (16
items), Stereotypic Behavior (7 items), Hyperactivity (16
items), and Inappropriate Speech (4 items). The BASC-2
was used to supplement the ABC-C data, as the ABC-C
does not specifically cover attention. The BASC-2 is a
comprehensive set of behavior-rating scales measuring
degree of clinically relevant problems, including aggres-
sion, anxiety, Attention Problems, atypicality, conduct
problems, hyperactivity, depression, somatization, and
withdrawal. All items are rated on a three-point scale.
There is a parent-rated version for children aged 6 to 11
years and adolescents aged 12 to 21 years, and a self-
rated version for adults over the age of 21 years. The
attention and hyperactivity clinical scales were chosen
for analysis as they were deemed most relevant to the
dimensions of Attention and inhibitory control on the
KiTAP. The Adaptability scale was also chosen for ana-
lysis, as it appeared most likely to show association with
the flexibility construct of the KiTAP. There are no
scales addressing attention that have been specifically
validated for FXS. The BASC-2 was chosen because it
has been extensively used to rate attention and hyperac-
tivity in children with complex behavior disorders, and
has been used in practice by our groups to evaluate
attention and distractibility in patients with FXS, parti-
cularly for females and higher-functioning males. The
children’s version of the BASC-2 was used for rating
individuals with FXS aged 6 to 11 years and the adoles-
cent version for individuals aged 12 years or older,
including adults (there were only three individuals in
the study with FXS over the age of 22 years). The ado-
lescent version was used for the adults with FXS (who
have substantially lower MAs) because these individuals
are unable to rate themselves (the adult form is self-
rated), and the questions on the adolescent version were
more appropriate for these individuals, whereas the
items on the adult form are largely not relevant to
adults with FXS.
Data analysis
Data analysis was performed using a spreadsheet (Excel;
Microsoft Corp., Redmond, WA, USA and SPSS soft-
ware (IBM, Armonk, NY, USA). Several measures from
each KiTAP subtest were analyzed including number
correct, errors, omissions, median reaction time, and SD
of median reaction time. Raw scores were used because
the normalized scores on the KiTAP previously gener-
ated from a typical population of children would not be
relevant to individuals with FXS. For each of these mea-
sures, the distribution of the scores was plotted, and the
intraclass correlation coefficient (ICC) was computed in
SPSS for measures that had an acceptable distribution
(normal distribution, and no ceiling, floor, or learning
effects) after outliers and non-valid data points (subject
not really participating) were eliminated. To examine
clinical relevance, Pearson correlations between KiTAP
scores and eight behavior checklist scores (five subscale
scores from the ABC-C and the three subscale T-scores
from the BASC-2) were calculated. For all subjects with
FXS and ID who had completed IQ testing, MA values
from the assessments were used as estimates of cogni-
tive level to allow determination of the minimum ability
required for valid testing in both children and adults
(for example, a given IQ in a child and adult will not
represent a comparable functional level) and to allow
MA-matching in the FXS/ID comparisons. Correlations
between MA and scores on KiTAP measures shown to
be valid and reliable were calculated. KiTAP subtest
scores in FXS and ID groups were compared using the
t-test. Because this was a pilot study, significance was
set at P = 0.05 for all comparisons, without adjustment
for multiple comparisons.
Results
Demographic information is shown in Table 1 for both
FXS and ID subjects. A wide range of chronological and
MAs was represented in both the FXS and ID groups,
and there was no significant difference at the initial test-
ing session in age, gender distribution, mental age
(Table 1), or KiTAP subtest performance between the
total FXS cohort and the group that was retested. The
ID group was significantly younger chronologically than
the FXS group (P = 0.01 for age comparison with both
total FXS cohort and retested FXS cohort).
In the feasibility analysis for the FXS group (Table 2),
the Attention, Distractibility, Go/NoGo, and Flexibility
subtests were all completed by the vast majority (> 90%)
of the participants. A little over half of the subjects were
able to complete the Vigilance and Visual Scanning
subtests. The Sustained Attention and Divided Attention
subtests could be performed only by eight and five of
the subjects, respectively; all these were subjects who
were high functioning and had clearly performed well
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on the previous six subtests. The majority of subjects
with FXS who completed a subtest during the first
round of testing were again able to complete the same
subtest when retested. The only exceptions to this were
two subjects who completed the Distractibility subtest
and one subject who completed the Visual Scanning
subtest at the first testing session, but not in the retest.
No subjects were able to perform the subtests in the ret-
est if they had been unable to do so in the initial testing
session.
Basal and ceiling effects were related to MA for the
subjects with FXS for whom we had valid IQ scores
(Table 2). Basal effects resulted predominantly from
unwillingness to complete the test or inability to engage
in the test with meaningful effort, and a ceiling effect
resulted from perfect scores in number correct, errors,
or omissions. The Alertness subtest was completed by
all participants, but ceiling effects were found for all
measures (aside from reaction time) for some subjects
with MA above 6.3 years and for all subjects with MA
above 7.8 years. For the Distractibility and Go/NoGo
subtests, some failures were found for subjects with MA
below 5.4 years, and a ceiling effect for some subjects
with MA above 7.1 and 7.0 years, respectively. Flexibility
was completed by all subjects whose MA was known,
and did not show a consistent ceiling effect with MA.
For the Vigilance and Visual Scanning subtests, failures
were found when MA was lower than 7.5 years. There
was also a ceiling effect for Vigilance when MA was
higher than 7.13 years, but no ceiling effect for Visual
Scanning. The Sustained Attention and Divided Atten-
tion subtest could not be completed by the majority of
Table 1 Demographic data for subject cohortsa
FXS ID cohort (n = 25)
Total cohortb Retested cohortc
Male Female Male Female Male Female
Chronological age, years
5 to 10 6 2 5 2 5 5
11 to 20 14 3 11 2 6 7
21+ 9 2 8 1 2 0
Mean ± SD 18.2 ± 10.03 17.5 ± 11.65 19.48 ± 10.77 13 ± 5.3 13.0 ± 6.02 11 ± 4.03
Range 7 to 50 9 to 44 7 to 50 9 to 21 5 to 24 5 to 18
Mental age, yearsd
2 to 4.99 2 0 2 0 2 3
5 to 6.99 5 2 4 2 5 2
7 to 11 10 5 10 4 6 7
Mean ± SD 6.6 ± 1.31 7.7 ± 1.18 6.6 ± 1.4 7.7 ± 1.3 7.6 ± 3.16 6.8 ± 2.92
Range 3.6 to 8.4 6.5 to 10.1 3.6-8.4 6.5 to 10.1 3.5 to 13.8 2.15 to 11.7
aAbbreviations: FXS, Fragile X syndrome; ID, intellectual disability; KiTAP, Test of Attentional Performance for Children.
bn = 36 and 24, respectively for chronological age and IQ.
cn = 29 and 22, respectively for chronological age and IQ.
dFor subjects with IQ scores available.
Table 2 Feasibility of KiTAP subtests in FXS cohort and MA for ceiling and basal effectsa
Subtest Performed testb Failed retest, n Performed test/retest, % MA, years (IQ, points)c
n % Some fail All fail Some ceiling Most ceiling
Alertness 36 100 0 100 NA NA > 6.3 (45) > 7.8 (52)
Distractibility 35 97 2 92 < 4.7 (52) NA > 7.1 (47) NA
Go-NoGo 35 97 0 97 < 3.6 (45) NA > 7.0 (47) NA
Flexibilityd 33 92 0 92 NA > 8.4 (60) NA
Vigilance 22 61 0 61 < 7.5 (50) < 5.4 (36) > 7.13 (47) > 8.1 (54)
Visual Scanning 20 56 1 53 < 7.5 (50) < 5.4 (36) NA NA
Sustained Attention 8 22 0 22 < 8.2 (55) < 7.1 (47) NA NA
Divided Attention 5 14 0 14 < 8.2 (55) < 7.1 (47) > 8.4 (60) NA
aAbbreviations: FXS, Fragile X syndrome; IQ, intelligence quotient; KiTAP, Test of Attentional Performance for Children; MA, mental age; NA, not applicable
bOut of 36 participants.
cIQs are also given for reference but as the subjects vary in age, these are less refective of the ability level required to do the task than the MA.
dThe mental age at which some subjects fail could not be derived for flexibility as IQ measures were not available for the three subjects who failed; however,
subjects with MA of 3.6, 4.7 and 5.4 years were successful in completing this task both times.
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the subjects, but no ceiling effects were seen for subjects
who did attempt the tests.
ICCs were calculated for measures that did not show
significant basal, ceiling, or learning effects, using data
from subjects who successfully completed both trials
(Table 3). After applying these criteria, eight measures
emerged with ICC of less than 0.6: Alertness reaction
time and SD of reaction time, Distractibility errors, Go/
NoGo errors and reaction time, Flexibility errors and
reaction time, and Vigilance reaction time.
Pearson correlations between KiTAP subtest scores
and clinical ratings of behavior as measured by the ABC-
C and BASC-2 are shown in Table 4. In general, mea-
sures of omission correlated poorly with reported beha-
vior in FXS; reaction time and commission errors tended
to correlate better. Of the measures with good reproduci-
bility, identified in the analyses above (Table 3), only the
Go-NoGo reaction time had no significant correlation
with clinical behavior; all other measures that showed
good reproducibility also correlated with at least one
measure of behavior. The specific behavioral correlates
most commonly seen were with Hyperactivity and Inap-
propriate Speech on the ABC-C, and Attention Problems,
Hyperactivity, and Adaptability on the BASC-2. In gen-
eral, these correlates appeared meaningful based on
target KiTAP measures and were in the expected direc-
tion (for example, more Go/NoGo errors correlated with
higher ABC-C and BASC-2 Hyperactivity, more Flexibil-
ity errors with higher BASC-2 Attention Problems and
worse Adaptability, and more Distractibility errors with
Table 3 Reproducibility of KiTAP measures with analysis of range and distribution of scores in FXS cohorta
KiTAP Measure Ceiling effects, n Range and distribution Revised ICCb




SD RT Good 0.89
Distractibility (n = 26) Correct 4
Omissions 1 Fair 0.56
Errors 4 Good 0.62
RT Skewed 0.89 (0.95 without outlier)
Go-Nogo (n = 28) Correct 7
Errors 6 Good 0.88
Omissions 7 Good 0.57
RT Good 0.88
SD RT
Flexibility (n = 27) Correct 0
Errors 1 Good 0.73
RT Fair 0.78
SD RT
Vigilance (n = 18) Correct 6 (trial 1);10 (trial 2) Too much ceiling, strong learning effect
Omissions 6 (trial 1); 10 (trial 2)
Errors 5 (trial 1); 13 (trial 2)
RT Good but had outliers 0.71 without outlier




Sustained Attention (n = 8) Correct 0 Too few could do test to get distribution
Omissions 0
Errors 0




aAbbreviations: FXS, Fragile X syndrome; KiTAP, Test of Attentional Performance for Children; RT, reaction time; SD, standard deviation
Performed using SPSS software.
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higher ABC-C Hyperactivity and BASC-2 Attention Pro-
blems). A summary of behavioral correlates with
KiTAP measures showing good reproducibility is given in
Table 5. Using an intercorrelation matrix for the seven
KiTAP measures showing good reproducibility and valid-
ity (measures shown in Table 5), several orthogonal mea-
sures and several with moderate intercorrelation were
identified (Table 6), indicating that that the measures are
not likely to be assessing entirely the same construct and
therefore have some independence.
Relationships between performance on the four
KiTAP subtests that could be completed by most sub-
jects (first testing session for subjects with FXS) and
level of function were compared for the FXS and ID
groups (Table 7). This analysis showed that many
KiTAP measures correlated with MA in both groups,
and in general, the relationships between the KiTAP
measures and MA showed a similar pattern for the FXS
and ID groups, suggesting a syndrome-independent gen-
eral relationship between level of function and KiTAP
performance. In the FXS group, performance on all
measures was not significantly different in the group
treated with psychotropic medication versus those who
were not, with the one exception of the Distractibility
errors, for which the treated group made more errors.
This seems unlikely to be a direct medication effect, and
may reflect a higher baseline distractibility level in those
who require medication and insufficient treatment of
the problem by the medication. In the ID group, medi-
cation treatment did not affect performance on any
measures except Flexibility, for which there was a longer
reaction time but fewer errors in the medication-treated
group, consistent with either an effect of medication on
performance or a characteristic of the group requiring
medication. The sample size was too small to analyze
Table 4 Correlation of KiTAP measures showing acceptable feasibility, reproducibility, range and distribution with








Median SD Median Median SD Median SD Median
ABC-C
Irritability 0.28 0.01 0.46* -0.03 0.11 -0.30 0.41* 0.38
Lethargy 0.16 0.43* 0.06 0.06 -0.19 -0.10 0.21 0.04
Stereotypy 0.21 0.28 0.35 -0.03 0.01 -0.26 0.34* 0.60**
Hyperactivity 0.49** 0.38* 0.41* 0.33* 0.08 -0.14 0.26 0.30
Inappropriate Speech 0.35* 0.26 0.51** -0.07 0.11 -0.23 0.29 0.64**
BASC-2-2
Hyperactivity 0.16 0.34* 0.26 0.36* 0.07 0.20 -0.34* 0.05
Attention Problems 0.27 0.25 0.41* 0.08 -0.17 0.47** -0.04 0.24
Adaptability -0.41* -0.42* -0.40* -0.06 -0.24 -0.34* -0.22 -0.38
Subjects for correlations
(ABC-C/BASC-2), n
27/25 27/25 23/22 26/24 26/24 27/25 27/25 18/17
aAbbreviations: ABC-C, Aberrant Behavior Checklist-Community Edition; BASC-2, Behavior Assessment System for Children, Second Edition; FXS, Fragile X
syndrome; KiTAP, Test of Attentional Performance for Children; RT, reaction time; SD, standard deviation
*P < 0.05, **P < 0.01.
Table 5 Summary of acceptable measures and behavioral
associations for the FXS cohort
KiTAP Measure Correlates
ABC-C BASC-2-2
Alertness ↑ RT with: ↑ hyperactivity** ↓ adaptability*
↑ inappropriate
speech*
Alertness ↑ SD RT with: ↑ hyperactivity* ↑ hyperactivity*,
↑ lethargy* ↓ adaptability*
Distractibility ↑ errors
with:
↑ hyperactivity* ↑ attention
problems*
↑ irritability* ↓ adaptability*
↑ inappropriate
speech**
Go-Nogo ↑ errors with: ↑ hyperactivity* ↑ hyperactivity*
Flexibility ↑ errors with: ↑ attention
problems**
↓ adaptability*
Flexibility ↑ RT with: ↑ stereotypy* ↓ hyperactivity*
↑ irritability*
Vigilance ↑ RT with: ↑ stereotypy** *
↑ inappropriate
speech*
aAbbreviations: ABC-C, Aberrant Behavior Checklist-Community Edition; BASC-
2, Behavior Assessment System for Children, Second Edition; FXS, Fragile X
syndrome; KiTAP, Test of Attentional Performance for Children; RT, reaction
time; SD, standard deviation.
*P < 0.05, **P < 0.01
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for effects of individual medications or classes of medi-
cations. Additionally, 16 MA-matched individuals were
chosen from each of the FXS and ID groups, with
chronological age matched as closely as possible so that
it was not significantly different between the two groups
of (13 ± 5.7 years for the ID group and 15 ± 5.8 years
for the FXS group, P = 0.25). Mean scores on KiTAP
subtests were compared, and a significant difference was
found for only two: the FXS group had fewer errors on
the Distractibility (P = 0.053), and more errors on the
Flexibility (P = 0.03) test.
Discussion
In this study, we sought to determine the feasibility, relia-
bility, and validity of the KiTAP in FXS. Our data demon-
strates that several measures from the KiTAP show an
adequate range and good feasibility, are relatively stable
over time, and are correlated with clinically meaningful
behavioral constructs. The KiTAP subtests had different
ranges of MA for which there were no ceiling, basal, or
learning effects, and thus subjects of all MAs received a
valid score on at least some of the subtests. In general,
however, a significant minority of subjects with FXS
could not perform the Vigilance and Visual Scanning
subtests, and the large majority could not perform the
Sustained Attention and Divided Attention subtests; the
former because of the subjects’ inability to maintain
attention and motivation long enough to complete the
task, and the latter because of the high level of task com-
plexity and the subjects’ inability to remember directions
for both auditory and visual stimuli
Each of the subtests that were feasible for the majority
of subjects with FXS had specific measures with an
acceptable range and distribution of scores, and good
test/retest reproducibility (ICC < 0.6). Finally, each of
these feasible and reproducible measures showed some
correlation with clinical behaviors, with the exception of
Go-NoGo reaction time, and these correlations were
mostly in the expected direction with respect to the clini-
cal behaviors. For example, subjects who scored higher in
Hyperactivity on ABC-C and BASC-2 tended to commit
more impulsive errors, and subjects who scored worse on
Adaptability tended to commit more errors on the Flex-
ibility subtest. However, reaction time data was more dif-
ficult to interpret. Indeed subjects showing shorter
reaction times on flexibility had higher hyperactivity rat-
ings. This may reflect a relationship between more
impulsive responding (and therefore shorter reaction
time) and hyperactivity on the BASC-2, although other
reaction time scores on KiTAP subtests seemed to be
positively correlated with hyperactivity, suggesting that
hyperactivity may result in more off-task behavior and
slower reaction time. These results are difficult to recon-
cile, but may be just an effect of small sample size that do
not reflect a clinical pattern. Our data suggest that some
scores on the KiTAP may reflect the severity of aspects
of the FXS phenotype, but this will require more study in
a larger sample.
Table 6 Correlation matrix for KiTAP measures meeting the criteria of acceptable feasibility, reproducibility, range,
distribution, and behavioral association.
Subtest Measure Alertness Distractibility Go-NoGo Flexibility Vigilance
RT SD RTb Errors Errors Errors RT RT
Alertness RT 1 0.763 (28)*** 0.127 (24) 0.105 (27) 0.416 (26)* -0.062 (26) 0.479 (17)*
SD RT - 1 -0.063 (24) 0.342 (27) 0.433 (26)* 0.094 (26) 0.228 (17)
Distractibility Errors - - 1 0.535 (28)** 0.095 (25) -0.195 (25) 0.263 (18)
Go-NoGo Errors - - - 1 0.151 (27) -0.458 (27)* -0.133 (18)
Flexibility Errors - - - - 1 -0.059 (27) 0.420 (18)
RT - - - - - 1 0.231 (18)
Vigilance RT - - - - - - 1
aAbbreviations: KiTAP, Test of Attentional Performance for Children; RT, reaction time; SD, standard deviation.
bPearson correlations (r values) are shown with number of tests on which the correlation is based given in parentheses. *P < 0.05, **P < 0.005, ***P < 0.0001
Table 7 Correlation between KiTAP and MA in the FXS
and ID cohorts.a
Test Measure Pearson correlations (r values)
FXS, n = 22 ID, n = 25
Distractibility Errors -0.24 -0.15
Omissions -0.04 -0.34*
Median RT 0.06 -0.37*
Alertness Median RT -0.57** -0.45*
SD RT -0.63*** -0.63***
Flexibility Errors -0.72*** -0.54**
Median RT 0.18 0.00
Go/No Go Errors -0.40* -0.27
Omissions -0.53** -0.56**
Median RT -0.52** -0.52**
aAbbreviations: FXS, Fragile X syndrome; KiTAP, Test of Attentional
Performance for Children; ID, intellectual disability; MA, mental age; RT,
reaction time; SD, standard deviation.
*P < 0.05, **P < 0.01, ***P < 0.0005
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It is difficult to know in the FXS population whether the
subtests of the KiTAP were specifically measuring the EFs
they were designed to measure. Despite the correlations
with the behavioral forms, which represent a crude screen
for clinical relevance, there is no validated EF measure or
CPT for cohorts with FXS, and therefore there is no stan-
dard for comparison to evaluate the specificity of the subt-
ests in FXS. Previously, CPTs have been used in FXS
cohorts in a clinical trial setting, and to measure medica-
tion effects on EF and attention in patients treated in clini-
cal practice. When administered to 48 adults with FXS in
a clinical trial, the IVA produced data that were impossible
to analyze [17]. In this studythe combination of auditory
and visual information appeared too complex for indivi-
duals with FXS to analyze, and the abstract, uninteresting
nature of the stimuli failed to hold the subject’s attention,
resulting in random responding. The North Carolina pro-
ject CPT has been subjected to some psychometric study,
and was used to track development of EF and to evaluate
effects of clinical stimulant treatment on attention trajec-
tories [29] in young males with FXS, but proved to have
insufficient range when used in a clinical trial with higher-
functioning male and female adults with FXS, thus sug-
gesting that it is useful only for a subset of young patients
[18].
We found that many, but not all, KiTAP measures cor-
related with MA, both in the FXS group and the ID group.
There was no association between chronological age and
KiTAP performance in either group, and for the MA-
matched FXS and ID groups used to compare the KiTAP
subtest scores, there was no significant difference in
chronological age, so age should not have been a factor
limiting the comparisons. For most KiTAP measures there
were no significant differences in score distributions
between the two groups for the different subtests, suggest-
ing that KiTAP gives a general measure of executive-func-
tion ability both in subjects with FXS and in those with
other causes of cognitive impairment. The difference in
flexibility scores, with worse performance in the FXS
group, is not unexpected given that perseveration is a pro-
minent feature of the FXS phenotype. However, it was
unexpected that the FXS group made fewer errors on the
Distractibility sub-test; this may be due to the high
demand for rapid visual processing inherent in the test
(stimuli are presented very rapidly) coupled with the rela-
tive strength in visual processing in FXS [30], or to some
other property of the specific subtest, or to random
chance, as the significance level was borderline.
This pilot study had a number of limitations related to
the sample of subjects examined.
1) The sample size is relatively small, although the
study was intended as a pilot study to help deter-
mine whether further work with the KiTAP in FXS
should be pursued. Given the relative rarity of FXS,
this study is similar in size to other pilot studies of
measures in FXS.
2) Not all subjects provided IQ results; however,
subjects with missing IQ scores were generally well
distributed across KiTAP scores and age. The one
exception to this rule was that the four subjects who
scored poorest on KiTAP across all subtests did not
have valid IQ scores. One of these subjects was
probably too low functioning to complete valid IQ
testing. The other subjects had very substantial clini-
cal issues with hyperactivity and distractibility, which
probably contributed to their lower scores.
3) Formal testing for autism was also not available
for the majority of the subjects in the cohort, and
thus the effects of autism status on performance
could not be assessed; however, this analysis was
outside the scope and purpose of the study in any
case, and would be a topic for further research.
4) Although medication overall did not seem to have
a major effect on group performance levels, it is pos-
sible that differences in the FXS and ID groups in
the fraction of subjects treated with medication (the
FXS group had a higher level of medication use)
could have affected the comparisons between the
two groups. More definitive analysis of medication
effects and an understanding of the effects of indivi-
dual medications on performance will require
further work with a larger sample size.
5) Although females with FXS generally have a
higher level of functioning than males, the number
of females enrolled was insufficient to generate a
sample size adequate to analyze their data separately
from the males, hence we cannot be absolutely sure
that the relationships between KiTAP performance
and BASC-2/ABC-C scores would be the same in
females and males.
6) The FXS and ID groups were tested at different
sites, and despite attempts to ensure similar proto-
cols and administration methods, differences in
administration technique could have affected the
results.
7) The KiTAP subtests were administered in a fixed
order, which may have affected the assessment of
subjects ability to perform the subtests administered
later in the battery, and the examiner prompts,
which were somewhat variably used across subjects,
were not counted systematically for analysis of their
effect on test feasibility and validity
8) The BASC-2 has not been formally normalized or
evaluated in FXS, and there may be better attention
measures to use for KiTAP validity analyses, although
no other parent-report attention measures have been
formally validated for FXS, and understanding the
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optimal measure for use to assess cohorts with FXS
will require further study.
9) Another potential limitation of the KiTAP is the
difficulty in defining a true floor for scores. Our cri-
teria for failing a subtest only included refusal or
inability to stay engaged. For a number of the subt-
ests, subjects who are engaged in the subtest may
receive a non-zero score, even if they do not under-
stand the idea behind the test. This could lead to a
situation in which a subject might have an improve-
ment in cognitive function that was not measured by
the test, if they remain beneath the threshold of actu-
ally understanding the test. However, the overall cor-
relation of measures with MA and clinical behavior is
reassuring that, in spite of this problem, KiTAP does
serve as a good measure of function.
10) Lack of immediate feedback during testing may
be a further limitation of the KiTAP. Because no
immediate feedback about incorrect or correct
responses is given by the KiTAP program during the
test, subjects might become confused about the pur-
pose of the test or disinterested in participating. The
RA administering the test addressed this problem by
frequently encouraging the subject to continue to
participate in the task and by giving positive feed-
back for participation.
11) However, this strategy does have the disadvantage
of adding another potential limitation: the subject
performance is made somewhat dependent on the
motivation and technique of the test administrator,
and creates problems in interpretation of the subject’s
innate attention/EF skills as measured by the task.
Such a limitation may be unavoidable with an FXS
population because of the difficulty in getting subjects
with FXS to finish the testing tasks at all without such
encouragement. We attempted to at least keep the
assessments consistent between subjects and trials by
using the same test administrator for all trials of a
given subject at each site, and creating a common
protocol for administering the test. Lack of feedback
about incorrect responses is likely to be helpful in
that subjects do not really experience a sense of fail-
ure or frustration about their inability to perform.
12) Finally, the KiTAP castle appears on first impres-
sion to appeal more to children than to adults with
FXS. Although older adult subjects may have been
less engaged by the castle theme than children, this
did not seem to specifically affect performance, as
many adults with FXS remain interested in and enjoy
cartoon characters, and some of the adults in the
study expressed interest in talking about the charac-
ters after the testing session. Regardless of age, the
castle ‘characters’ seemed to sustain attention and to
be of greater interest than the abstract stimuli used in
the IVA and other standard CPTs. Validated compu-
terized EF batteries with adult visual themes are an
area that could be explored in future test develop-
ment and validation.
Specific measures on the KiTAP that emerged as feasi-
ble for the majority of subjects were Alertness reaction
time, SD of Alertness reaction time, Distractibility errors,
Go/NoGo errors, Flexibility errors, Flexibility reaction
time, and Vigilance reaction time (Table 5). These mea-
sures did not produce excessive ceiling, basal, or learning
effects, exhibited an acceptable range and distribution of
scores, had good to excellent reproducibility, and corre-
lated with meaningful behavior ratings. Six of these seven
measures were contained in four subtests: Alertness, Dis-
tractibility, Go/NoGo, and Flexibility. In our experience
administering the KiTAP, we found that these tests also
have the advantage of each requiring less than 5 minutes
to administer, as opposed to other subtests, which
required 10 to 15 minutes. This allowed the majority of
subjects to complete all four of these subtests without
significant fatigue, a definite advantage for assessments
involving subjects with FXS. Thus, we feel that these four
subtests are best suited for use in future studies, and
because this pilot study has shown that most patients
with FXS can complete these subtests, the effects of test
order can be further evaluated by randomizing the order
of administration in future studies. Further, more work
could be carried out to evaluate the characteristics of the
Vigilance, Visual Scanning, Sustained Attention, and
Divided Attention Subtests in a larger high-functioning
FXS sample with MA of greater than 10 years to deter-
mine whether these are useful measures of response in
high-functioning FXS cohorts, particularly females.
Conclusions
In this pilot study, some measures on at least some
subtests of the KiTAP showed adequate feasibility, relia-
bility, and clinical validity for subjects with FXS across a
wide range of function. This is in contrast with previous
CPTs which have not allowed meaningful administration
to such a range of individuals with FXS without produ-
cing substantial ceiling and floor effects [17,18]. Given
the difficulties with rater bias and placebo effects that
accompany behavioral rating forms addressing EF
domains even with optimal administration practices, the
KiTAP may be a useful objective outcome measure of
attention and executive function for use in FXS clinical
trials, and even to track medication responses in clinical
practice. Further work is needed to evaluate the respon-
siveness of the KiTAP to pharmaceutical or other
interventions.
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